Skip to main content
OpenTrials

Clinical trial condition

Advanced Urothelial Carcinoma

Explore clinical trials studying Advanced Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

24 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Advanced Urothelial Carcinoma trial results

Not yet recruiting

Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer

NCT07793578

Conditions
Advanced Urothelial Carcinoma
Locations
  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT West Haven, Connecticut, United States
  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA Boston, Massachusetts, United States
  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA Philadelphia, Pennsylvania, United States
  • VA Puget Sound Health Care System Seattle Division, Seattle, WA Seattle, Washington, United States
View Trial Details
Active, not recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

NCT00365157

Conditions
Advanced Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +9 more
Locations
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope Antelope Valley Lancaster, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 26 locations
View Trial Details
Active, not recruiting

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235

Conditions
Advanced Urothelial Carcinoma, Open Label, Oral Drug Administration
Locations
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Sylvester Comprehensive Cancer Center, University of Miami Miami, Florida, United States
  • The University of Chicago Medicine Chicago, Illinois, United States
View Trial Details
Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

NCT04491942

Conditions
Adenoma, Adnexal Diseases, Advanced Bile Duct Carcinoma, +72 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, United States
View Trial Details
Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, not recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552

Conditions
Advanced Solid Tumor, Advanced Urothelial Carcinoma, Bladder Cancer, +31 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • UMass Memorial Medical Center Worchester, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center (MSKCC) New York, United States
  • Duke Cancer Institute (DCI) - Duke Cancer Center Durham, North Carolina, United States
View all 19 locations
View Trial Details

Related conditions